JP2019535262A5 - - Google Patents

Info

Publication number

JP2019535262A5

JP2019535262A5 JP2019524412A JP2019524412A JP2019535262A5 JP 2019535262 A5 JP2019535262 A5 JP 2019535262A5 JP 2019524412 A JP2019524412 A JP 2019524412A JP 2019524412 A JP2019524412 A JP 2019524412A JP 2019535262 A5 JP2019535262 A5 JP 2019535262A5

Authority

JP

Japan

Prior art keywords

nucleic acid

car

acid sequence

sequence encoding

cell

Prior art date

2017-11-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 94
• 150000007523 nucleic acids Chemical group 0.000 claims description 88
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 73
• 210000004027 cell Anatomy 0.000 claims description 58
• 239000000427 antigen Substances 0.000 claims description 50
• 102000036639 antigens Human genes 0.000 claims description 50
• 108091007433 antigens Proteins 0.000 claims description 50
• 238000000034 method Methods 0.000 claims description 22
• 125000006850 spacer group Chemical group 0.000 claims description 20
• 239000013598 vector Substances 0.000 claims description 19
• 201000010099 disease Diseases 0.000 claims description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
• 239000003795 chemical substances by application Substances 0.000 claims description 16
• 108020004707 nucleic acids Proteins 0.000 claims description 15
• 102000039446 nucleic acids Human genes 0.000 claims description 15
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
• 102000001493 Cyclophilins Human genes 0.000 claims description 14
• 108010068682 Cyclophilins Proteins 0.000 claims description 14
• 239000012190 activator Substances 0.000 claims description 14
• 229910052791 calcium Inorganic materials 0.000 claims description 14
• 239000011575 calcium Substances 0.000 claims description 14
• 239000003446 ligand Substances 0.000 claims description 14
• 239000008194 pharmaceutical composition Substances 0.000 claims description 14
• 210000000066 myeloid cell Anatomy 0.000 claims description 8
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 6
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 6
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
• 108020004705 Codon Proteins 0.000 claims description 4
• 102000004127 Cytokines Human genes 0.000 claims description 4
• 108090000695 Cytokines Proteins 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 206010052015 cytokine release syndrome Diseases 0.000 claims description 4
• 108010002082 endometriosis protein-1 Proteins 0.000 claims description 4
• 230000006801 homologous recombination Effects 0.000 claims description 4
• 238000002744 homologous recombination Methods 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 229920001184 polypeptide Polymers 0.000 claims description 4
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
• 230000028327 secretion Effects 0.000 claims description 4
• 239000013603 viral vector Substances 0.000 claims description 3
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 claims description 2
• 238000003776 cleavage reaction Methods 0.000 claims description 2
• 230000004186 co-expression Effects 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 238000009169 immunotherapy Methods 0.000 claims description 2
• 230000003993 interaction Effects 0.000 claims description 2
• 230000031146 intracellular signal transduction Effects 0.000 claims description 2
• 230000004068 intracellular signaling Effects 0.000 claims description 2
• 230000036210 malignancy Effects 0.000 claims description 2
• 210000003519 mature b lymphocyte Anatomy 0.000 claims description 2
• 230000007017 scission Effects 0.000 claims description 2
• 230000002463 transducing effect Effects 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 17
• 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 3
• 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 3
• 241000700605 Viruses Species 0.000 claims 1
• 241001430294 unidentified retrovirus Species 0.000 claims 1
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 1